Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Biotechnologie

Mr. Charles F. Wagner Jr.

Executive Vice President & Chief Financial Officer

Dr. David M. Altshuler M.D., Ph.D.

Executive Vice President & Chief Scientific Officer

Ms. Kristen C. Ambrose CPA

Senior Vice President & Chief Accounting Officer

Dr. Reshma  Kewalramani FASN, M.D.

Chief Executive Officer, President & Director

Ms. Nina  Devlin

Senior Vice President & Chief Communications Officer

Mr. Stuart A. Arbuckle B.Sc.

Executive Vice President & Chief Operating Officer

Susie  Lisa

Senior Vice President of Investor Relations

Mr. Jonathan  Biller J.D.

Executive Vice President & Chief Legal Officer

Mr. Mike  Tirozzi

SVice President and Chief Information & Data Officer

Dr. Jeffrey Marc Leiden M.D., Ph.D.

Executive Chairman

Name	Marktkapitalisierung
Sorrento Therapeutics, Inc.	0M
Maravai LifeSciences Holdings, Inc.	0M
Comera Life Sciences Holdings, Inc.	0M
Gubra A/S	0M
CytoTools AG	0M
Hofseth BioCare ASA	0M
Shanghai Haohai Biological Technology Co., Ltd.	0M
Purple Biotech Ltd.	0M

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated Liste der Konkurrenten

Wichtigste Wettbewerber